Cargando…

Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial

BACKGROUND: The AIO KRK-0104 randomised phase II trial investigated the efficacy and safety of two capecitabine-based regimens: combination of capecitabine and irinotecan (CAPIRI) plus cetuximab (CAPIRI-C) and combination of capecitabine with oxaliplatin (CAPOX) plus cetuximab (CAPOX-C) in the first...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stintzing, S, Fischer von Weikersthal, L, Vehling-Kaiser, U, Stauch, M, Hass, H G, Dietzfelbinger, H, Oruzio, D, Klein, S, Zellmann, K, Decker, T, Schulze, M, Abenhardt, W, Puchtler, G, Kappauf, H, Mittermüller, J, Haberl, C, Giessen, C, Moosmann, N, Heinemann, V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3142807/ https://www.ncbi.nlm.nih.gov/pubmed/21750558 http://dx.doi.org/10.1038/bjc.2011.227

Ejemplares similares

Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial
por: von Einem, J. C., et al.
Publicado: (2014)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: The AIO KRK 0110 Trial/ML22011 Trial
por: Giessen, Clemens, et al.
Publicado: (2011)

Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205
por: Hoehler, T, et al.
Publicado: (2013)

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
por: Stintzing, S, et al.
Publicado: (2019)

Capecitabine and bevacizumab for non-resectable metastatic colorectal cancer patients: final results from phase II AIO KRK 0105 trial
por: Stein, Alexander, et al.
Publicado: (2013)

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104
por: Boeck, S, et al.
Publicado: (2013)

Standard diametric versus volumetric early tumor shrinkage as a predictor of survival in metastatic colorectal cancer: subgroup findings of the randomized, open-label phase III trial FIRE-3 / AIO KRK-0306
por: Hofmann, Felix O., et al.
Publicado: (2022)

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104
por: Ormanns, Steffen, et al.
Publicado: (2014)

Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212)
por: Modest, Dominik Paul, et al.
Publicado: (2022)

Impact of sex on the efficacy and safety of panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS WT metastatic colorectal cancer (mCRC). Subgroup analysis of the PanaMa-study (AIO-KRK-0212)
por: Heinrich, K., et al.
Publicado: (2023)

Amphiregulin (AREG) and Epiregulin (EREG) Gene Expression as Predictor for Overall Survival (OS) in Oxaliplatin/Fluoropyrimidine Plus Bevacizumab Treated mCRC Patients—Analysis of the Phase III AIO KRK-0207 Trial
por: Stintzing, Sebastian, et al.
Publicado: (2018)

EMT-Related Genes Have No Prognostic Relevance in Metastatic Colorectal Cancer as Opposed to Stage II/III: Analysis of the Randomised, Phase III Trial FIRE-3 (AIO KRK 0306; FIRE-3)
por: Pretzsch, Elise, et al.
Publicado: (2022)

FIRE-9 – PORT / AIO-KRK-0418: a prospective, randomized, open, multicenter Phase III trial to investigate the efficacy of adjuvant/additive chemotherapy in patients with definitely-treated metastatic colorectal cancer
por: Raschzok, Nathanael, et al.
Publicado: (2022)

Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2020)

Study protocol of the FIRE-8 (AIO-KRK/YMO-0519) trial: a prospective, randomized, open-label, multicenter phase II trial investigating the efficacy of trifluridine/tipiracil plus panitumumab versus trifluridine/tipiracil plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer
por: Sommerhäuser, G., et al.
Publicado: (2022)

Correction: Bacterial lipopolysaccharide as negative predictor of gemcitabine efficacy in advanced pancreatic cancer – translational results from the AIO-PK0104 Phase 3 study
por: Guenther, Michael, et al.
Publicado: (2021)

Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
por: Modest, D. P., et al.
Publicado: (2016)

Capecitabine-associated hand–foot–skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer
por: Hofheinz, R-D, et al.
Publicado: (2012)

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)
por: Kurreck, A., et al.
Publicado: (2020)

Aios in coronatijd
por: Maria Greijn, Claudia, et al.
Publicado: (2020)

Geriatric assessment and the variance of treatment recommendations in geriatric patients with gastrointestinal cancer—a study in AIO oncologists
por: Büttelmann, M., et al.
Publicado: (2023)

Monte Carlo simulations of Higgs-boson production at the LHC with the KrkNLO method
por: Jadach, S., et al.
Publicado: (2016)

OA01.04. The effectiveness and cost effectiveness of acupressure for chemotherapy-related nausea
por: Hughes, J, et al.
Publicado: (2012)

NLO Corrections to Hard Process in Parton Shower MC - KrkNLO Method
por: Jadach, S, et al.
Publicado: (2015)

AIOS proceedings: A response
por: Rajendran, Babu
Publicado: (2009)

19. AIO-Herbstkongress 2022
Publicado: (2023)

Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma—a phase II trial of the AIO study group (AIO STO 0321)
por: Tintelnot, Joseph, et al.
Publicado: (2023)

Matching NLO QCD with parton shower in Monte Carlo scheme — the KrkNLO method
por: Jadach, S., et al.
Publicado: (2015)

PA01.04. Clinical study of shvadmstradi kwatha in the management of mutra ashmari (urinary calculi)
por: Thameem, Mohammed
Publicado: (2013)

PA01.04. Assessment of acharrasayan in domain of physical, mental & social health in Ayurveda students
por: Desai, Priti, et al.
Publicado: (2012)

Evaluation of prognostic factors in liver-limited metastatic colorectal cancer: a preplanned analysis of the FIRE-1 trial
por: Giessen, C, et al.
Publicado: (2013)

Exact Primary Tumor Location in mCRC: Prognostic Value and Predictive Impact on Anti-EGFR mAb Efficacy
por: Alig, Annabel H. S., et al.
Publicado: (2022)

OA01.04. Ayurvedic management of chronic rheumatoid arthritis with severe deformities - A case report
por: Sujithra, RM, et al.
Publicado: (2013)

P01.04. Learning From Within: Peer-based Group Coaching Among Undergraduate Students
por: Sommers, Jayne, et al.
Publicado: (2013)

Trends and Challenges in AIoT/IIoT/IoT Implementation
por: Hou, Kun Mean, et al.
Publicado: (2023)

Risk Factors for Development of Hemolytic Uremic Syndrome in a Cohort of Adult Patients with STEC 0104:H4 Infection
por: Zoufaly, Alexander, et al.
Publicado: (2013)

OA01.04. Management of ankylosing spondylitis through ayurvedic medicine along with agnikarma- A case study
por: Tamrakar, Anupam, et al.
Publicado: (2012)

AIOS Constitution Reforms - Change is the Secret Sauce for Success
por: Honavar, Santosh G
Publicado: (2021)

AIoT Used for COVID-19 Pandemic Prevention and Control
por: Chen, Shu-Wen, et al.
Publicado: (2021)

Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials
por: Noepel-Duennebacke, Stefanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rnrgg6irv9p73mkfjgn08jv9bn